Under one in 10 people who could benefit from obesity jabs including Wegovy are able to get them, warns the global health agency as it issues its inaugural advice on the medications.
Given in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just availability to these injectable treatments.
Per forecasts, more than two billion could be living with obesity by 2030 without intervention.
"The latest guidance acknowledges that excess weight is a long-term condition that can be treated with thorough and lifelong care," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are key obstacles to widespread availability to the jabs that can aid individuals in losing considerable body mass, notes the body.
Weight-Loss Drug Scarcity
Despite the present most favorable case, the production of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, as stated by the health organization.
The recommendation calls on governments and firms to expand access, via measures like patent sharing.
A patent on semaglutide – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in a number of countries in 2026.
The Way Obesity Injections Function
These medications imitate a biological compound to reduce digestion speed, reduce hunger and increase satiety so users reduce food intake.
Patients commonly begin shedding pounds in the initial weeks of commencing the regular doses.
Evidence points to users may see weight return after a year of discontinuing the treatment, when their typical appetite come back.
Being carrying excess weight raises your likelihood for developing diseases, such as diabetes, cardiovascular issues, brain attack, and some malignancies.
Obesity impacts people in every country and was linked to millions of fatalities worldwide in 2024, per the health agency.
